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Abstract
Brain Derived Neurotrophic Factor (BDNF) signalling contributes to the formation, maturation and plasticity of
Central Nervous System (CNS) synapses. Acute exposure of cultured brain circuits to BDNF leads to up-regulation of
glutamatergic neuro-transmission, by the accurate tuning of pre and post synaptic features, leading to structural
and functional synaptic changes. Chronic BDNF treatment has been comparatively less investigated, besides it may
represent a therapeutic option to obtain rescue of post-injury alterations of synaptic networks. In this study, we
used a paradigm of BDNF long-term (4 days) incubation to assess in hippocampal neurons in culture, the ability of
such a treatment to alter synapses. By patch clamp recordings we describe the augmented function of excitatory
neurotransmission and we further explore by live imaging the presynaptic changes brought about by long-term
BDNF. In our study, exogenous long-term BDNF exposure of post-natal neurons did not affect inhibitory
neurotransmission. We further compare, by genetic manipulations of cultured neurons and BDNF release,
intracellular overexpression of this neurotrophin at the same developmental age. We describe for the first-time
differences in synaptic modulation by BDNF with respect to exogenous or intracellular release paradigms. Such a
finding holds the potential of influencing the design of future therapeutic strategies.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a member
of the neurotrophin family crucial to brain and spinal
cord development [1, 2]. Exposure to BDNF during
development stimulates axonal branching [3, 4], den-
dritic growth [4, 5], and refinement of synapses in an
activity-dependent manner [6]. In addition, BDNF pro-
motes the formation of both excitatory and inhibitory
synapses and increases their maturation [7].
Among the members of the neurotrophin family,
BDNF stands out for its ability to regulate synaptic
plasticity and various cognitive functions of the brain
[8]. Indeed, BDNF, when acutely delivered, has been
shown to affect synaptic transmission and plasticity
[9–11]. In particular, a rapid enhancement of excita-
tory neurotransmission has been demonstrated in
dissociated hippocampal cultures [12–16] and in cul-
tured neuromuscular synapses [17–19]. BDNF modu-
lates also inhibitory transmission, albeit through
different mechanisms [20, 21]. BDNF potentiates
excitatory synapses via pre- and post-synaptic mecha-
nisms [22, 23]. Presynaptically, BDNF increases
glutamate release, thus enhancing the frequency of
miniature excitatory postsynaptic currents (mEPSCs)
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in hippocampal neurons [16, 24]. On the postsynaptic
side, BDNF augments NMDA receptor single channel
opening probability [15, 25–27]. In addition, BDNF
up-regulates the expression of voltage-gated Ca2+ and
Na+ channels at the plasmamembrane [4]. Regarding
the inhibitory synaptic transmission, BDNF is needed
to regulate maturation of γ-aminobutyric acid
(GABAergic) synapses in the hippocampus [28, 29].
Acute BDNF application reduces inhibitory synaptic
transmission in the hippocampus, where both evoked
and spontaneous GABAergic currents are decreased
via TrkB receptor [30, 31]. Finally, acute application
of the mature form of BDNF on hippocampal slices
facilitates the early phase of long-term potentiation
(LTP [32–34];).
Of note, the role of chronic BDNF exposure in regu-
lating long-lasting changes in synaptic function has been
comparably less investigated. It was shown that long-
term treatment (72 h) of hippocampal slices with BDNF
(250 ng/mL) increases synapse number and spine density
at the level of apical dendrites of pyramidal neurons in
the hippocampus [35], suggesting that BDNF acts select-
ively on different types of spines, depending on the level
of basal, spontaneous synaptic transmission. In addition,
it was suggested that long-lasting BDNF treatment might
play a role on post injury alteration of synaptic networks
and neuronal rescue [10]. Although elevated levels of
BDNF have been shown to persist for several days fol-
lowing nerve injury [36–38], the large majority of studies
examining its action on dorsal horn neurons have used
acute, short-term exposures [39–41]. In this study, we
used hippocampal cultures, electrophysiology, live im-
aging, immunofluorescence and genetic transfections to
fill the existing gap of information on long-term actions
of BDNF on synaptic dynamics.
Results
Long-term BDNF treatment improves excitatory synaptic
current frequency and amplitude
To investigate the ability of prolonged exposure to
BDNF to regulate network dynamics and synaptic trans-
mission, dissociated hippocampal cultures were treated
for 4 days with 20 nM mature BDNF (named BDNF-
treated cultures) and compared to untreated ones
(named Controls). Spontaneous postsynaptic currents
(PSCs) were recorded using single cell patch-clamp elec-
trophysiology to monitor the activity of the networks
grown for 8~10 days in Control and BDNF-treated cul-
tures. The appearance of PSCs provides clear evidence
of functional synapse formation [42, 43] and we selected
a time in vitro at which synaptic currents are present,
but characterized by a relatively low frequency [44, 45].
Figure 1a, (top), shows representative current tracings
depicting the basal synaptic activity in cultured neurons.
Neuronal passive properties were routinely measured in
Control neurons (n = 44) and BDNF-treated ones (n =
75) which did not differ in terms of cell capacitance
(78 ± 5 pF in Control and 96 ± 6 pF in BDNF-treated), in-
put resistance (500 ± 53MΩ Control and 477 ± 47MΩ)
and resting membrane potential (− 47 ± 1mV for
Control and − 50 ± 1mV for BDNF-treated). Conversely,
in BDNF-treated neurons, baseline PSCs displayed a sig-
nificant increase (P < 0.001; one-way ANOVA) in ampli-
tude (from 111.9 ± 13.3 pA in Controls to 157.2 ± 19.1
pA in BDNF cultures; n = 19 and n = 26, respectively;
summarized in the bar plot of Fig. 1b, left) and in fre-
quency (from 1.2 ± 0.3 Hz in Controls to 2.7 ± 0.3 Hz in
BDNF-treated; Fig. 1b, right). In cultured hippocampal
networks, neurons typically display either GABAA or
glutamate AMPA receptor-mediated PSCs [46, 47],
which were both detected as inward currents in our re-
cording conditions (see methods) [42, 45]. Thus, we
identified the different populations of PSCs on the basis
of their kinetic properties and pharmacology [42, 48].
GABAergic PSCs were identified by their slow decay
time constant (τ = 25.4 ± 1.0 ms, n = 45; Fig. 1a, bottom
left), inverted polarity at − 35mV holding potential and
were abolished by 10 μM bicuculline (n = 25). Gluta-
matergic AMPA receptor-mediated PSCs were identified
by their fast decay (τ = 5.4 ± 0.2 ms, n = 46; Fig. 1a,
bottom right), inverted polarity around 0mV holding
potential and were completely removed by 10 μM
CNQX (n = 30). In BDNF treated cultures, the frequency
of fast excitatory PSCs (EPSCs) was significantly
increased when compared to Controls (from 0.88 ± 0.24
Hz in Control to 2.16 ± 0.31 Hz in BDNF-treated; n = 24
and n = 38, respectively; P < 0.001 one-way ANOVA,
Fig. 1c, left) as well as their amplitude (from 74.2 ± 1.4 pA
in Control to 146.4 ± 2 pA in BDNF-treated; P < 0.001
Mann-Whitney’s test; the cumulative probability distribu-
tion of EPSCs amplitudes is shown Fig. 1d; P < 0.001
Kolmogorov-Smirnov’s test). Differently, not significant
differences were detected in GABAA receptor mediated
PSCs (IPSCs) frequency (from 0.40 ± 0.08Hz in Control
to 0.60 ± 0.08Hz in BDNF-treated; n = 21 and n = 36,
respectively; P = 0.19 Student’s t-test; Fig. 1c, right) or
peak amplitude (from 152 ± 6 pA Control, to 182 ± 4 pA
BDNF-treated; P = 0.45 one-way ANOVA) when compar-
ing BDNF-treated with respect to Control.
In subsequent experiments, we tested BDNF exogen-
ous applications at two shorter incubation times, 24 and
48 h, to explore whether, also in these conditions, the
prolonged exposure to the neurotrophins was selectively
targeting glutamatergic synapses, leaving GABAergic
ones unaffected. In BDNF-treated cultures at 24 h and at
48 h the frequency of EPSCs was significantly increased,
with respect to Control (at 24 h: from 0.21 ± 0.06 Hz
Control to 0.75 ± 0.31 Hz BDNF-treated, n = 6 cells each
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group, P = 0.023 Mann-Whitney’s test; at 48 h: from
0.36 ± 0.09 Hz Control to 0.80 ± 0.14 Hz BDNF-treated,
n = 6 cells each group, P = 0.015 Mann-Whitney’s test;
Fig. 1e, left). Conversely, the frequency of IPSCs
remained unchanged (at 24 h: 0.19 ± 0.09 Hz Control
and 0.17 ± 0.05 Hz BDNF-treated, P = 0.59 Student’s
t-test; at 48 h: 0.12 ± 0.04 Hz Control and 0.17 ± 0.05 pA
BDNF-treated, P = 0.46 Student’s t-test; Fig. 1e right). In
Fig. 1 Long-term BDNF exposure augments glutamatergic excitatory synaptic currents. In (a) top panel: voltage clamp recordings of spontaneous
synaptic activity of Control (black trace) and BDNF treated (blue trace) cultures; bottom panel: average tracings of spontaneous GABAA receptor
(slow events; left) and AMPA-glutamate (fast events; right) receptor mediated PSCs, note the different decay time. In (b) bar plots reporting PSCs
amplitude (left) and frequency (right), significantly (P < 0.001, one-way ANOVA) increased by BDNF exposure. In (c) bar plots reporting EPSCs (left;
significantly increased when compared to Control; P < 0.001, one-way ANOVA) and IPSCs (right) frequency following BDNF treatment. Note the
different scale of EPSCs and IPSCs in the frequency plot. In (d) cumulative distribution of amplitude values of Control (grey) and BDNF (blue)
EPSCs (Kolmogorov-Smirnov test; P < 0.001). In (e) plots reporting EPSCs frequency (left) increased (P < 0.05, Mann-Whitney test) after 24 and 48 h
long lasting BDNF treatments respect to Controls, while IPSCs frequency (right) is unchanged. In (f) cumulative distribution of amplitude values of
Control (grey) and BDNF (blue) EPSCs after 24–48 h (P < 0.0045 Kolmogorov-Smirnov’s test)
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Fig. 1f, the cumulative probability distribution (24 h and
48 h were pooled together; P < 0.0045 Kolmogorov-
Smirnov’s test) shows the increase in EPCSs peak
amplitude following BDNF treatments when compared
to Control (from 29 ± 1 pA Control to 36 ± 1 pA BDNF-
treated, P < 0.0001, Mann-Whitney’s test). Conversely,
IPSCs peak amplitudes were unchanged (77 ± 4 pA
Control and 64 ± 4 pA BDNF-treated, P = 0.065,
Mann-Whitney’s test).
Long-term BDNF treatment affects neuronal survival and
synaptic components
Neural network efficacy depends on neurons and synap-
ses. Thus, to estimate changes in these structural entities
we evaluated the dynamic of network size during devel-
opment in the two culture groups, since neuronal cell
density might influence network activity. We used im-
munofluorescence to image the specific cytoskeletal
components β-tubulin III to identify neurons, and glial
fibrillary acidic protein (GFAP) to visualize astrocytes
(Fig. 2a). We sampled cultures prior to BDNF incubation
by measuring neuronal densities and estimating the
number of pyramidal cells identified by morphological
criteria (see methods; Fig. 2a, white arrows) [49–51].
β-tubulin III positive cell density before treatment was
208 ± 55 neurons/mm2, with 34 ± 7 pyramidal cells/mm2
(n = 10 visual fields, four different series of cultures; bar
plot of Fig. 2b). After 4 days, we detected 154 ± 51 neu-
rons/mm2 (25 ± 6 pyramidal cells/mm2) in Control and
196 ± 49 neurons/mm2 (49 ± 10 pyramidal cells/mm2) in
BDNF-treated (n = 13 visual field per condition, four
different series of cultures; P < 0.001, two-way ANOVA;
Fig. 2b). This result suggests that BDNF treatment globally
sustains neuronal survival and, in particular, that of excita-
tory pyramidal cells [49].
We then addressed whether these changes in network
size and cellular composition were accompanied by
changes in synapses. Accordingly, we recorded miniature
EPSCs (mEPSCs; Fig. 2c) in a subset of Control and
BDNF-treated neurons in the presence of the fast inacti-
vating voltage-gated sodium channel blocker, tetrodo-
toxin (TTX, 1 μM), which impairs the action potentials.
The analysis of mEPSCs allows assessing synaptic func-
tional and structural components. In particular, mEPSCs
reflect the stochastic release of vesicles from the pre-
synaptic terminals and their frequency depends on the
Fig. 2 Long-term BDNF exposure impacts neuronal survival and excitatory synapses. In (a) Immunofluorescence images showing neuronal and
glial cells in Control (left) and BDNF (right) conditions (anti-β-tubulin III, in red; anti-GFAP, in green; in all, nuclei are visualized by DAPI in blue). In
(b) the plots summarize neuronal densities and pyramidal cells density on Control (in grey) and after BDNF exposure (in blue) compared to
cellular densities before any treatment (in green); striped bars refer to all neuronal cells while plain bars refer to pyramidal ones. In (c) sample
tracings of mEPSCs recorded in Control (black trace) and BDNF (blue trace) treated cultures. In (d) cumulative distribution of mEPSCs amplitude
values of Control (grey) and BDNF (blue) EPSCs (Kolmogorov-Smirnov test; P < 0.001). In (e) bar plots reporting mEPSC frequency values. BDNF
treatment significantly increased the frequency of mEPSCs (P < 0.001, one-way ANOVA)
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presynaptic release probability and on the number of
synaptic contacts, whereas their amplitude depends on
postsynaptic receptor [42, 52]. We found that mEPSC
amplitude was increased by BDNF-treatments when
compared to Control (from 30 ± 0.7 pA Control to
53.4 ± 2.0 pA BDNF-treated, n = 9 and n = 17, respect-
ively). When plotting the cumulative probability distri-
bution of mEPSCs peak amplitude values (Fig. 2d), a
highly statistically significant difference (P < 0.001,
Kolmogorov-Smirnov test) was detected between Con-
trol and BDNF-treated cultures. BDNF also significantly
increased the frequency of mEPSCs (from 0.06 ± 0.02 Hz
in Control to 0.40 ± 0.08 Hz in BDNF-treated neurons;
P < 0.001, one-way ANOVA; bar plot in Fig. 2e). These
results suggest that, upon BDNF treatment, both func-
tional and structural synaptic components are affected.
Long-term BDNF treatment affects functional components
of synapses
To further inspect synaptic features in cultured neuronal
networks, we exploited simultaneous dual patch-clamp
recordings of mono-synaptically connected neurons. Ac-
tion potentials were induced in the presynaptic neuron
and the evoked postsynaptic unitary PSCs (delay 2 ms)
were examined (see methods; representative traces in
Fig. 3a). In these experiments, we detected only a small
fraction of gap junctions-coupled neurons, in accordance
with previously reported results [42]. Due to the low
probability of finding gap-junction-coupled pairs, those
detected were not further analysed. The percentage of
cell pairs that exhibited a detectable unitary connection
(coupled pairs) was strongly increased by BDNF treat-
ments (from 20% in Control to 70% in BDNF-treated,
n = 26 pairs and n = 38 pairs, respectively). We further
evaluated the nature of mono-synaptic connections, by
assessing the PSC decay, pharmacology and reversal po-
tential. In BDNF-treated cultures, the large majority
(80%) of mono-synaptically coupled pairs were AMPA
receptor-mediated and evoked fast EPSCs (τ = 5.0 ± 0.6
ms) while in Control cultures, the 80% of pairs were
GABAA receptor mediated and evoked slow IPSCs (τ =
23.0 ± 0.8 ms). These results are summarized in the bar
plot of Fig. 3b.
We turned then our attention to the presynaptic
properties of glutamatergic unitary synapses by adopting
paired-pulse stimulation protocols with short inter-
stimulus interval (50 ms; Fig. 3a), where the second re-
sponse can be either facilitated or depressed. At unitary
synapses an increased probability of neurotransmitter
release (pr) favours paired-pulse depression, whereas a
decrease in the pr favours facilitation [53–55]. We esti-
mated the pr by quantifying the paired-pulse ratio (PPR;
see methods) [56, 57]. While the PPR values for unitary
GABAergic couples were not affected by BDNF
treatment (bar plot Fig. 3c), glutamate AMPA-receptor
mediated couples exhibited in Control a PPR value of
3.2 ± 0.3 (n = 5 pairs; Fig. 3c) indicating the presence of a
strong facilitation [42], while in BDNF-treated neurons
the measured PPR of 0.7 ± 0.06 (n = 10 pairs) was ex-
pression of a depression at these synapses.
Altogether, these experiments strongly suggested an
increased survival of glutamatergic (pyramidal) neurons
and increased synaptogenesis, along with modulation of
pre and postsynaptic components of glutamatergic con-
nections upon BDNF long-term treatments. Therefore,
we focused the next set of experiments on presynaptic
modifications, in particular the pr. We measured the kin-
etics of synaptic vesicle release by real-time imaging of
vesicles labelled with styryl dye FM1–43 dye [58–61] to
monitor the rate of presynaptic vesicle recycling from
hippocampal neurons treated or untreated by BDNF. In
these experimental conditions we could not discriminate
between GABAergic and glutamatergic neurons and
synapses, however we focused on presynaptic terminal
of presumed pyramidal neurons (see methods; Fig. 3d,
left column). Following FM1–43 labelling, clusters of
presynaptic puncta were visible as bright fluorescence
spots (Fig. 3d, middle and right columns, at 2 different
times). The effect of BDNF on the size of recycling pool
of synaptic vesicles was estimated by measuring the raw
fluorescence intensity of individual FM1–43 positive
puncta, that is proportional to the number of vesicles
endocytosed during synaptic vesicle recycling, following
high KCl (50 mM [62];) depolarization, that is propor-
tional to the number of vesicles endocytosed during syn-
aptic vesicle recycling [58]. As shown in Fig. 3e, we
detected a significant increase (P < 0.001, Mann-Whitney
test) in puncta fluorescence intensity in BDNF-treated
neurons (from 126.7 ± 35.7 a.u. in Control to 164.6 ±
42.4 a.u. in BDNF treated, mean ± SD, 459 and 409
puncta, respectively; n = 5 coverslips from 3 independent
cultures for each condition), indicating that long-term
treatment with BDNF increased the size of the pool of
recycling vesicles. When analysing the decay time
constant (τ; n = 459 terminals, Control; n = 425 termi-
nals, BDNF-treated; n = 3 series of cultures) of the FM1–
43 fluorescence de-staining profiles during vesicle
exocytosis, we observed a difference in the kinetics dis-
played by Control and BDNF-treated synapses, as shown
in Fig. 3f. In reference experiments, the image series
captured on FM1–43 stained cells, but without the high-
K+ de-staining stimulus, produced a baseline reference
plot (see Fig. 3f, bleaching). By analysis of the kinetic of
single de-staining events, we could identify two categor-
ies of responses (see example in Fig. 3g): “fast” events
showing an initial (20 s) fluorescence drop fitting an ex-
ponential decay with τ of 13.27 ± 2.74 s (mean ± S.D.,
n = 133 terminals of 3 different experiments), and “slow”
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Fig. 3 BDNF exposure affects pre-synaptic release. In (a) sample tracings of simultaneous pair recordings: top, evoked monosynaptic GABAergic
PSCs in Control (black) and glutamate-AMPA receptor mediated in BDNF-treated (blue) cultures; bottom, presynaptic induced action potentials. In
(b) plots summarize the probability of finding evoked GABAA- or AMPA- receptor mediated pair recordings in Control (grey) or BDNF (blue)
treated cultures. In (c) is summarized the paired-pulse ratio (PPR) of GABAA- or AMPA-mediated PSCs measured in Control and BDNF treated
pairs. In (d) sequence of images Control, above and BDNF, below: sequential FM1–43 staining and destaining: (left image) bright field images
show the extensive neurite arborization that hippocampal neurons reach at 9÷10 DIV culture; (middle image): the same fields after staining with
FM1–43; (right image): fluorescence images following destaining induced by 50 mM KCl. Remaining fluorescence represents non-specific staining.
In (e) histograms summarized the averaged fluorescence intensity when loaded with FM1–43. BDNF-treated cells showed a significant increase
(P < 0.001, Mann-Whitney test) compared to Control cultures. In (f) the rate of synaptic release from synaptic terminals, following KCl stimulation,
in Control (black line) and BDNF (blue line) cultures. In grey the natural fluorescent bleaching after KCl stimulation. In (g) representative single de-
staining fast (orange line) and slow (pink) profiles, based on their kinetics properties. In (h) plots summarize the distribution of fast and slow
events in Control (grey) and BDNF-treated (blue) cultures. Note that in BDNF-treated cells prevailed fast events (on the left), while in Control
cultures, the large majority displayed slow events (on the right)
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events displaying τ of 27.87 ± 3.96 s (n = 176 terminals of
3 different experiments; P < 0.001, two-way ANOVA).
The two categories of events were differently distributed
among Control and BDNF-treated samples, in that “fast”
events prevailed on BDNF-treated cultures (57.8% ± 11.7
of the total events population; n = 425 terminals,
variation from Control “fast” events with significance of
P < 0.001 by two-way ANOVA test; Fig. 3h), while “slow”
events predominated in Controls (83.4% ± 4 of the total
events population; n = 459 terminals, difference from
BDNF slow events with significance of P < 0.001, two-
way ANOVA test; Fig. 3h).
Investigating the role of intracellular BDNF
overexpression
Since the results described above were obtained by treat-
ing neuronal cell cultures with exogenous BDNF, we
designed a series of experiments to investigate the role
of intracellular BDNF overexpression in modifying the
activity of the cultured hippocampal network. Neurons
at 8~10 DIV were recorded after 24 and 48 h from trans-
fection with a plasmid encoding a specific BDNF-in
fusion with GFP to allow identification of BDNF overex-
pressing cells. This construct (CDS-BDNF-GFP) is
known to drive a local BDNF production and release in
the cell body and in all proximal and distal compart-
ments of dendrites [63–65]. By using voltage clamp re-
cordings (Fig. 4a for sample tracings), we compared GFP
transfected Control (n = 11, from now on tGFP) vs.
CDS-BDNF-GFP transfected neurons (from now on
tBDNF; 24 h tBDNF n = 11; 48 h tBDNF n = 8, 48 h).
Passive membrane properties were not affected by BDNF
production and release (tGFP capacitance 63 ± 7 pF, at
24 h tBDNF 53 ± 6 pF and at 48 h tBDNF 58 ± 6 pF; in-
put resistance 210 ± 46MΩ, 300 ± 84MΩ and 270 ± 32
MΩ, respectively for tGFP, tBDNF 24 h, tBDNF 48 h).
In tBDNF neurons (24 h and 48 h), we detected a
strong increase (P < 0.001, two-way ANOVA) in PSCs
amplitude (70 ± 15 pA, in tGFP, 141 ± 15 pA in tBDNF
24 h and 152 ± 13 pA in tBDNF 48 h) and frequency
(1.7 ± 0.5 Hz in tGFP, 4.3 ± 0.7 Hz in tBDNF 24 h and
4.9 ± 0.8 Hz in tBDNF 48 h), summarized in Fig. 4b.
BDNF intracellular production and release affected all
synaptic components, regardless of the transmitter in-
volved. Figure 4c and d summarize these results, show-
ing that in tBDNF (24 h and 48 h) both EPSCs and
IPSCs were improved in amplitude and frequency. These
results confirmed that the BDNF coding region, com-
mon to all transcripts [64] is sufficient to induce signifi-
cant changes in the hippocampal synaptic transmission
in cultures.
In the same set of experiments, we monitored the abil-
ity of intracellular over-expression of BDNF to impact
neighbour cells (n = 11) not expressing CDS-BDNF-GFP
(named ne-tBDNF). ne-tBDNF cells (distant ~ 100 μm
from tBDNF ones; under visual microscope Control)
were recorded at 24 h and 48 h, from the tBDNF cul-
tures. ne-tBDNF cells displayed no differences in terms
of capacitance and input resistance (50 ± 6 pF and 232 ±
28MΩ, respectively). Figure 4e and f summarises results
related to EPSCs and IPSCs frequency and amplitude
values with respect to Control (tGFP): in ne-tBDNF we
detected an increase in EPSCs frequency at 24 h and 48
h, without changes in EPSCs amplitude, while IPSCs
parameters were not affected. These results suggest that
localized production and secretion of BDNF can modu-
late pre and post synaptic activity locally, without effects
on distant non-expressing neurons, besides those neu-
rons reflecting the overall network increased activity.
Eventually, we ascertained by confocal analysis, the
presence of TrkB receptors at inhibitory synapses by co-
labelling of cultured hippocampal neurons (Control
untreated ones) for the TrkB receptor and for the
VGAT, the vesicular GABA transporter considered a
GABAergic presynaptic marker [42]. Figure 5 A qualita-
tive analysis of the putative co-localization unequivocally
demonstrated the presence of TrkB receptors at inhibi-
tory synapses, distributed in the expected subcellular
districts, namely the soma and the proximal domains of
the apical and basal dendrites.
Discussion
In this study, we show that prolonged (4 days-, 24 h-
and 48 h-long) treatments with exogenous BDNF in DIV
4 hippocampal neurons, increased both amplitude and
frequency of the excitatory synaptic activity recorded at
DIV 8~10, leaving inhibitory synapses unchanged.
Furthermore, we demonstrate that an intracellular over-
expression of BDNF for 24 h or 48 h in hippocampal
neurons increases both the amplitude and the frequency
of the excitatory as well as inhibitory synaptic activity.
The targeting of glutamatergic synapses by BDNF is in
agreement with previous studies [21, 35, 66–69]. We
hypothesize that several converging mechanisms
contributed to the up-regulation of excitatory synapses
following chronic treatment with exogenous BDNF. We
documented an increased survival of neurons in BDNF-
treated cultures and, in particular, the doubling of
survived pyramidal neurons, usually displaying a higher
ratio in excitatory glutamatergic synapses than other
cells [49]. The emergence of a larger network, character-
ized by an increased excitation/inhibition ratio, might
contribute to the enhanced network activity [70]. Re-
gardless the network size, we cannot rule out that a
higher cellular excitability induced by BDNF [4] could
be, at least in part, responsible for our results. Several
pieces of experimental evidence suggest that a target re-
finement of structural and functional components of
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Fig. 4 BDNF intracellular production and release affects all synaptic components. In (a) representative voltage clamp recordings of spontaneous
activity in tGFP (green trace) and tBDNF (red trace; 24 h) cultures. In (b) plots reporting PSCs amplitude (left) and frequency (right), significantly
(P < 0.001, two-way ANOVA) increased by BDNF expression (24 h and 48 h). In (c) plots reporting EPSCs (left) and IPSCs (right) frequency,
significantly (P < 0.001, two-way ANOVA) increased by intracellular BDNF (24 h and 48 h) compared to Control sister cultures. In (d) plots reporting
EPSCs (left) and IPSCs (right) amplitude significantly (P < 0.001, two-way ANOVA) increased by intracellular BDNF (24 h and 48 h) compared to
Control sister cultures. In (e) and (f) EPSC and IPSC frequency and amplitude values are depicted recorded from ne-tBDNF. In respect of Control
(tGFP) only EPSP frequency values were significantly affected (P < 0.01 24 h, P < 0.05 48 h, two-way ANOVA)
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glutamatergic synapses took place during long-term
exposure to the neurotrophin. Our results with mini-
ature postsynaptic (PSC) recordings in TTX after BDNF
treatment clearly support, in parallel with changes in the
sensitivity of the postsynaptic cells to glutamate [26, 68,
71, 72], an enhancement in neurotransmitter release
probability and in the number of releasing sites, in
agreement with previous studies [73]. In particular, we
show that BDNF treatment increases the probability of
functional pairing between excitatory cells. The regula-
tion of these presynaptic mechanisms is strengthened by
our results in postsynaptic responses to paired-pulse
stimulation, and by live imaging experiments, indicating
variations in presynaptic transmitter release. Indeed, we
found that BDNF induced an increased rate of FM1–43
release, leading to an increased percentage of fast release
events with respect to Control cultures where slow ones
prevail. Although the kinetics of styryl dye de-staining
might account for multiple events, possibly comprising
different steps of both exo- and endocytosis [74–76],
these results reinforce the view that long-term treatment
of hippocampal neuronal cultures with BDNF increases
both the size and the availability of the releasable synap-
tic vesicle pool [68, 73]. In this framework, prolonged
application of exogenous BDNF may also accelerate syn-
apse maturation by inducing the expression of AMPA
Fig. 5 Colocalization of TrkB-full length receptor and VGAT. In (a) confocal images showing hippocampal neurons (Control culture) (anti-TrkB, in
green; anti-VGAT, in red; nuclei are visualized by Hoechst in blue). Merge of the TrkB and VGAT channels or merge of the three channels are
shown in dual o three-colour. The black and white image shows the colocalized TrkB and VGAT pixels. Note the presence of TrkB receptors at
inhibitory synapses in the soma and the proximal domains of the apical and basal dendrites. Calibration bar: 10 μm. In (b) schematic summary of
the proposed actions of BDNF when locally released at glutamatergic or GABAergic synapses
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receptors and by stimulating their insertion in the plas-
mamembrane at the post-synaptic densities. Thus, an
enhancement in mEPSC frequencies and amplitudes, as
observed in our study, might also result from postsynap-
tic modifications; namely, the activation of postsynaptic
silent glutamatergic synapses [16].
While the increased responsiveness of glutamatergic
synapses with long-term bath application of BDNF is in
perfect agreement with one previous study [69] we ob-
tained novel findings with intracellular expression of
BDNF-CDS.
In the present study, exogenous application of BDNF
did not elicit significant changes in inhibitory PSCs. In
previous studies, prolonged application of exogenous
BDNF was shown to promote the formation/maturation
of GABAergic synapses by presynaptic modifications
[20, 21, 31, 68, 77], while evidence of post-synaptic ef-
fects, such as membrane expression of GABAA recep-
tors, are comparatively more limited [29, 78]. Several
experimental differences concerning animal and culture
ages may explain these contrasting results. First, in our
study BDNF (20 nM) was bath-applied for 4 days from
DIV 4 until DIV 8 (or DIV 6 to DIV 10) while in the
other studies neurons were treated from DIV 1 for 1 or
2 weeks, at different BDNF concentrations ranging from
25÷100 ng/mL. Second, we used hippocampal neurons
explanted from post-natal rats, while the other studies
used E18 embryos [20, 21, 29, 31, 77, 78]. Of note, one
study in which no effects on GABAergic synapse could
be found [69] used DIV 12–14 primary cultures of
hippocampal neurons treated with bath application of
100 ng/mL BDNF for 48 h. These discrepancies might be
explained in the light of the effects of BDNF at different
ages and concentrations. Young postmitotic neurons are
very sensitive to BDNF dosage, while mature neurons
are less sensitive and use different mechanism of re-
sponse. In fact, intracellular overexpression of BDNF at
early developmental stages induced raising of expression
of K+/Cl−KCC2 co-transporter, which is responsible for
the conversion of GABA responses from depolarizing to
hyperpolarizing, and increased spontaneous co-active
network activity, without altering the expression of
GABA and glutamate ionotropic receptors [79]. In con-
trast, BDNF application on mature neurons is unable to
affect synaptic vesicle release at inhibitory synapses while
it increases spontaneous synaptic vesicle release at
excitatory synapses [69]. We cannot exclude that other
factors, such as low BDNF concentration ranges, when
applied exogenously, influenced the synaptic outcomes
of prolonged treatments. The concentration used in our
work for exogenous BDNF applications is 20 nM, which
is within the range of those reported by previous works
(Reviewed in [80, 81]). Interestingly, our results are also
in agreement with Shinoda et al. [69], where
experiments were performed using a 48 h exposure with
a lower concentration (~ 4 nM). Thus, apparently, using
a concentration ~ 5 times higher did not affect the syn-
aptic outcomes. It has been reported that acute or grad-
ual increases in BDNF might influence downstream
signaling [82], regardless TrkB being maximally phos-
phorylated in 5 min at 1 nM BDNF concentration. The
possibility that, more than the final concentration of
BDNF, is the mode of delivery which might impact its
effects [82] cannot be excluded.
In a previous study, we have shown that the neuronal
growth and maturation in vitro of both mouse and rat
hippocampal neurons can be subdivided into six stages
[44] which is a revision of the previous subdivision into
5 stages of the establishment of neuronal polarity, ori-
ginally proposed by Dotti et al. [83] (reviewed in [84]).
Thus, here we applied BDNF in a time window, which,
according to the new staging system, spans the whole
stage 4 (DIV 4÷6) and the beginning of stage 5 (DIV
7÷11) [44]. During Stage 4, neurons are still immature
and primary dendrites assume a stable morphology while
higher order dendrites and axons undergo progressive
growth [44]. During Stage 5, apical dendrites undergo to
highly dynamic series of protrusions and retractions [44,
85]. It is during Stage 5 that synapses become stabilized
and the first, yet sparse, spontaneous action potentials
are expressed [44].
Regardless the potential relationship between develop-
mental stages and BDNF preferred targeting of excita-
tory synapses, we found here that the delivery route
might impact synaptic targeting. We observed, for the
first time, that intracellular overexpression of BDNF for
24 and 48 h within the developmental stage 5 elicited
not only a significant increase in amplitude and fre-
quency of excitatory PSCs but also of inhibitory ones.
Although we did not further investigate synaptic
changes due to BDNF over expression, we put forward
the provocative hypothesis that the BDNF delivery route
is crucial to achieve postsynaptic effects. Several investi-
gations have provided definitive evidence that transfec-
tion of a plasmid encoding GFP-tagged BDNF coding
sequence leads to expression of the chimeric mRNA in
the neuronal soma and dendrites, but also to transport
of the GFP-tagged protein from the soma into dendrites
and axons [63, 65, 86–89]. In particular, in neurons
transfected with this plasmid, the overexpressed GFP-
tagged BDNF can be locally translated from mRNA lo-
calized in the dendritic compartment, in proximity to
synapses leading to local secretion and spatially re-
stricted activation of TrkB receptors [64]. Interestingly,
the results obtained from these in vitro studies corres-
pond to the BDNF-GFP distribution observed in a recent
in vivo study using a knock-in mouse [90]. The reason is
that the coding sequence of BDNF contains
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constitutively active dendritic targeting signals, recruit-
ing Translin and other RNA-binding proteins, that are
sufficient to induce localization of BDNF mRNA in dis-
tal dendrites in unstimulated neuronal cultures [63],
while the 3’UTR short and the 3’UTR long of BDNF
contains signals that induce enhanced dendritic targeting
of BDNF mRNA in response to neuronal activity [91].
Therefore, we can assume that even in this work, BDNF-
GFP proteins are actually synthesized in the soma and in
the dendrites. This localized production and secretion of
BDNF from postsynaptic sites, is postulated to produce
specific punctual effects on the synapses that are releas-
ing this neurotrophin both through an autocrine loop
impacting on the dendrite itself, as well as through a
retrograde signalling affecting presynaptic terminal ([65,
92]; scheme in Fig. 5b). In our study, this potential
mechanism is reinforced by the recordings from ne-
tBDNF distinct neurons and by the detected co-
localization of TrkB receptors and VGAT positive
presynaptic terminals. An impairment of this mechanism
has been associated with memory deficits in mice and
humans [93]. Another mechanism which may underlay
the differences observed between exogenous and en-
dogenous long-term BDNF application, may involve the
ability of glial cells, in particular astrocytes, to uptake
circulating BDNF [94, 95], thus leading to different
effects.
Conclusions
In conclusion, the results of the present study suggest
that intracellular overexpression of BDNF in developing
neurons, provides a more complete and physiological
stimulus to induce maturation of excitatory and inhibi-
tory synapses, with respect to exogenous application of
BDNF. Previous attempts to use intravenous or intra-
thecal delivery of exogenous BDNF for the treatment of
neurodegenerative diseases have failed [96, 97]. Thus,
current therapeutic approaches have been redirected to
delivery of mesenchymal cells overexpressing BDNF [98]
or to viral-mediated gene therapy in the CNS parench-
ima [99]. In this framework we perceived as relevant to
provide a detailed analysis of the differential synaptic
outcomes of BDNF treatments through bath application
vs genetic delivery in cultured neuronal networks.
Methods
Preparation of primary cultures
Dissociated rat hippocampal cultures were prepared
from 2- to 3-days postnatal (P2-P3) animals as previously
reported [42, 48]. All procedures were approved by the
local veterinary authorities and performed in accordance
with the Italian law (decree 26/14) and the UE guidelines
(86/609/CE, 2007/526/CE, and 2010/63/UE). The animal
use was approved by the Italian Ministry of Health. All
efforts were made to minimize suffering and to reduce
the number of animals used. All chemicals were
purchased by Sigma-Aldrich unless stated otherwise. En-
zymatically dissociated cells [42, 48] were plated at a
density of 200.000 ± 16.000 cells/mL (values sampled
form n = 4 cultures) on poly-L-ornithine-coated glass
coverslips (Kindler, EU) in 35 mm Petri dishes. Cultures
were incubated in a 5% CO2 humidified incubator in
medium MEM supplemented to reach 35 mM glucose,
1 mM Apo-transferrin, 15 mM HEPES, 48 μM insulin,
3 μM biotin, 1 mM vitamin B12, 500 nM gentamicin, and
10% dialyzed foetal bovine serum (FBS; Gibco). Culture
medium was renewed after 2 days from seeding and
contained additionally an inhibitor of glial cells prolifera-
tion, cytosine arabinoside (Ara C, 10 μM). After 4 days
in vitro, cultures were treated for a further 24 h, 48 h or
4 days with 20 nM Brain-Derived Neurotrophic Factor
(BDNF). Cultured cells were used for experiments at
8~10 days in vitro.
Electrophysiological recordings
Single and paired patch-clamp recordings in the whole-
cell configuration were obtained at room temperature
(RT) with glass pipettes (5–7 MΩ) containing (in mM):
120 K gluconate, 20 KCl, 10 HEPES, 10 EGTA, 2 MgCl2,
2 Na2ATP, pH 7.3; osmolarity was adjust to 300mOsm.
The extracellular solution contained (in mM): 150 NaCl,
4 KCl, 1 MgCl2, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glu-
cose, pH 7.4. Either an EPC-7 amplifier (List, Germany)
or a Multiclamp 700B (Axon CNS, Molecular Devices)
patch amplifier were used for voltage clamp recordings
with the cell voltage clamped to − 56 mV holding poten-
tial (not corrected for junction potential, that was 14
mV). For current clamp recordings we used an
Axoclamp 2B amplifier (Molecular Devices LLC, Axon
Instrument, US) or a Multiclamp 700B under bridge-
balance mode. Current and voltage clamp responses
were digitized using a Digidata 1322A or a Digi-
data 1440A (Molecular Devices LLC, US) at 10 KHz
with the pClamp 10.2 acquisition software (Molecular
Devices LLC, USA) and stored for further analysis. In
paired recordings, the presynaptic neuron was held
under current clamp mode at − 70mV (≤0.02 nA nega-
tive current injection), and action potentials were elicited
by injecting short (4 ms) square current pulses (1 nA).
The postsynaptic cell was voltage clamped at − 56 mV
holding potential. Monosynaptic connections were rec-
ognized by their short latency (< 5 ms [100];), measured
between the peak of the evoked action potential and the
onset of the postsynaptic current response. We
addressed the presence of gap-junctions by delivering
hyperpolarizing current steps (− 0.05 nA impulses, 100ms
in duration [101];). All recorded events were analyzed off-
line with the AxoGraph 1.4.4 (Axon Instrument) event
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detection software (Axon CNS, Molecular Devices). To
characterize the short-term dynamics of synaptic contacts,
we delivered to pairs of connected neurons (n = 6 Control
and n = 10 BDNF-treated) paired pulse stimulations at 20
Hz (every 20 s; 10 times that were pooled together and av-
eraged [48];). We measured the paired-pulse ratio (PPR,
calculating the ratio between the mean peak amplitude of
the second and the first PSC [48]).
Immunofluorescence staining
Hippocampal cells, Control and BDNF-treated, were
fixed by 4% formaldehyde (prepared from fresh parafor-
maldehyde; Sigma) in PBS at RT for 20 min. They were
permeabilized with 0.1% Triton X-100 and blocked in
1% foetal bovine serum (FBS) in PBS for 30 min to pre-
vent unspecific binding of antibodies. After incubation
with the primary antibodies (rabbit polyclonal anti-β-
tubulin III, 1:500 dilution; mouse monoclonal anti-
GFAP, 1:500 dilution) for 1 h at RT, cells were incubated
for 30 min with the secondary antibodies Alexa Fluor
594 goat anti-rabbit (Invitrogen, 1:500 dilution), Alexa-
Fluor 488 goat anti-mouse (Invitrogen, 1:500 dilution)
and with DAPI (Invitrogen, 1:200 dilution) to stain the
nuclei. Samples were mounted in Vectashield (Vector
Laboratories) on 1 mm thick coverslips. Cell density was
quantified at 20 ×magnification using a Nikon Eclipse
Ti-U fluorescence microscope with random sampling of
ten fields (Control and BDNF treated, n = 4 culture
series each). Neuronal densities were calculated for the
central area and for the periphery (distal areas) of the
glass coverslip by manual counting after the calibration
of the microscope field of view. The shape of the soma
and the processes organization and number were used
to identify pyramidal neurons [49]. Specifically, cells with
a triangular soma of 12–18 μm dimeter and with at least
one thick process were assumed to be pyramidal [49,
51]. Offline analysis was performed with the image-
processing package Fiji [102].
Colocalization of TrkB-full length receptor and VGAT
Unstimulated Control neurons were permeabilized with
PBS/0.1% Triton-X100, blocked with 1% BSA in PBS/
0.1%Triton-X100 and co-stained for 1.5 h with 1:500
anti-TrkB (R&D Lab) (secondary 1:200 anti-goat Alexa-
488 in green) and with 1:250 (mouse) monoclonal anti-
body against the vesicular GABA transporter (VGAT)
anti-VGAT antibodies (Synaptic Systems) (secondary
anti-mouse Alexa-568 in red) in PBS/0.1% Triton-X100.
Nuclei were labelled by 5 min incubation with Hoechst/
PBS (in blue).
Images were taken with a 60 × oil immersion objective
on a Nikon C1si spectral Confocal microscope and
deconvoluted using the standard protocol of Huygens
19.1 (Scientific Volume Imaging BV, Hilversum-The
Netherlands). Merge of the TrkB and VGAT channels or
merge of the three channels are shown in dual o three-
colour. The black and white image shows the colocalized
TrkB and VGAT pixels extracted with Huygens. The
qualitative analysis indicates the presence of TrkB recep-
tors at inhibitory synapses mostly located in the soma
and the proximal domains of the apical and basal den-
drites. Co-localization extends into secondary and in
part tertiary dendrites, but is very rare in distal dendritic
regions which are known to be characterized by low
density of inhibitory synapses.
FM1–43 fluorescence imaging
Depolarization-dependent staining of synaptic terminals
with the styryl dye N-(3-triethylammoniumpropyl)-4-(4-
(dibutylamino) styryl) pyridinium dibromide (FM1–43,
Molecular probes, Life Technologies Corporation) was ob-
tained by incubating cultures (after 10min saline buffer
wash at RT) for 120 s with 2mL of saline solution contain-
ing 50mM KCl and 15 μM FM1–43 dye. The buffer was
replaced with 2mL of normal saline solution containing
FM1–43, and cells were left to recovery for 10min to
ensure complete recycling of the vesicles and then
incubated for 10min with saline containing 10 μM 6-
cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 50 μM
2-aminophosphonovaleric acid (2-APV) to prevent net-
work activity altering the rate of FM release. These antag-
onists were present throughout the experiment. Images
were continuously acquired by a Till Photonics Till-Imago
system, exciting the FM1–43 dye with a 475 nm wave-
length generated by a monochromator (Polychrome IV,
Till Photonics GMBH, Grafelfing, Germany) and acquir-
ing fluorescence images using a 800 × 600 pixels CCD
camera (CCD Imago type super VGA, Till Photonics; 1
frame/second, 50ms exposure) interfaced to the TillVi-
sion software (Till Photonics). Application of 50mM KCl
(2min), followed by a 2min washout, was used to stimu-
late vesicle endocytosis from the dye-containing terminals,
measured as a fluorescence loss. Offline analyses were
performed on image sequences with TillVision software.
Time-dependent fluorescence changes on FM1–43 la-
belled terminals were obtained by drawing regions of
interest (ROIs) around fluorescent spots (typically 6 × 6
pixels), including as little background possible. A compari-
son of the brightness of total vesicle pool puncta (raw
fluorescent intensity) in BDNF-treated and Control
cultures before the unloading stimulus gave an estimate of
the number of vesicles endocytosed during FM1–43 load-
ing. The decay time costant, τ, was measured using Origin
Pro 7.5 sofware (OriginLab Co., US).
Plasmid preparation and transfection
Plasmids were previously described [63] and contained a
preproBDNF-GFP construct inserted in a pEGFP-N1
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vector (Clontech). Primary hippocampal neurons were
transfected with Lipofectamine 2000™ (Life Technology,
Invitrogen) [103]. Cells were transfected with 1 μg of
plasmid DNA diluted in 50 μL of MEM medium without
serum and antibiotics. At the same time 2 μL of the
Lipofectamine™ solution (1 mg/mL) have been dispersed
in 50 μL of MEM solution. After 5 min the two solutions
have been mixed together, let for 20 min stabilizing at
RT, diluted to a final concentration of 20 nM and then
added to the cellular culture medium for transfection.
After 1 h incubation the Lipofectamine-DNA mixture
has been carefully removed and replaced with culture
medium. GFP-alone transfected neurons were used as
Control.
Statistical analysis
All values from samples subjected to the same experimental
protocols were pooled together and results are presented as
mean ± S.D., if not otherwise indicated; n = number of cells,
if not otherwise indicated. All data were compared using
parametric and nonparametric tests (Student’s t test,
Mann-Whitney or Kolmogorov-Smirnov test) as well as
one-way and two-way ANOVA, adjusting comparison by
Bonferroni or Holm-Sidak correction. Statistical signifi-
cance was determining at P < 0.05.
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